Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.

In this episode, we discuss:

Lars’ experience overcoming Treatment-Resistant Depression with psilocybin
The nuances of clinical trials and psilocybin dosing protocols
Compass Pathways’ Intellectual Property strategy
What additional indications and therapies Compass Pathways is interested in

Links to topics discussed in this episode:
Compass Pathways, Lars Wilde
COMP360
SSRI, SNRI
Christian Angermayer, Robin Carhart-Harris, Michael Pollan
Vivaneo
Quercis Pharma
TRD (Therapy-Resistant Depression)
Compass Phase 2B Trial
Jazz Pharmaceuticals
Compass Pathways 2 US patents
Oregon Psilocybin Therapy Measure 109

Read the transcript here.
Watch episode 10 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Hosts: Matias Serebrinsky and Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: River Meditation by Jason Shaw and Thea by Muted Circus

Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde